US Patent 9,393,237 (Paroxetine 7.5 mg/day for Menopausal Thermoregulatory Dysfunction): Claim Scope, Coverage Map, and US Patent Estate Analysis
US Drug Patent 9,393,237 is directed to a method of treating menopausal thermoregulatory dysfunction (hot flashes/hot flushes/night sweats and combinations) in female patients by administering paroxetine at 7.5 mg/day (paroxetine-moiety basis). The independent claim is narrow on patient population, indication, and dose, while dependent claims broaden coverage across salt forms and solid-state forms (crystalline/amorphous; anhydrate/hydrate/solvate).
The most commercially relevant take is that the patent is a dose-and-method claim. It is enforceable against labelled/used dosing regimens and generic products whose prescribing/administration practices fall within the claim language, even if the generic formulation differs, provided the regimen and forms match the claim limitations.
What is the claim scope of US 9,393,237 for paroxetine 7.5 mg/day hot flashes?
Core invention (Claim 1)
- Method for treating female patients with thermoregulatory dysfunction associated with menopause
- Treating a condition consisting of hot flashes, hot flushes, night sweats, and combinations
- Administering a dosage form of paroxetine
- Dose: 7.5 mg/day based on the paroxetine moiety
Practical meaning
- The claim is triggered by how the drug is used, not by a specific manufacturing process.
- The dose constraint is strict: 7.5 mg/day is a central limiting element. Any regimen outside that dose range is a potential non-infringement route.
- The indication constraint is likewise central: if thermoregulatory symptoms are not treated “associated with menopause,” the clinical use may fall outside the claim.
How does Claim 1 constrain infringement risk (dose and patient identity)?
Claim 1 imposes three enforceability levers:
- Sex and menopause association
- Applies to female patients.
- Requires that thermoregulatory dysfunction is associated with menopause.
- Thermoregulatory symptom definition
- Hot flashes/hot flushes/night sweats and combinations.
- Dose
- Paroxetine dosage is 7.5 mg/day on a paroxetine-moiety basis.
How broad are the dependent claims on salt forms and solid-state forms?
Claims 3–14 layer on additional formulation parameters. These are important for litigation because they define whether different paroxetine forms still infringe.
Salt-form coverage (Claims 4–10)
Dependent claims specify that the dosage form may comprise a pharmaceutically acceptable salt of paroxetine, with nested lists:
- Claim 4: “pharmaceutically acceptable salt of paroxetine”
- Claim 5: hydrohalides, sulfates, phosphates, oxalate, tosylate, pamoate, citrate, carbonate, bicarbonate, maleate, malate, fumarate
- Claim 6: specifically hydrochloride, hydrobromide, hydroiodide, and combinations
- Claim 8: sulfate and bisulfate and combinations
- Claim 7: paroxetine hydrochloride
- Claim 9: paroxetine mesylate
- Claim 10: mono/di/tri basic phosphates
Breadth assessment
- The salt list is broad across multiple pharmaceutically acceptable acid addition salts.
- The claim language is not limited to a single counterion. That reduces generic “form switching” leverage.
Free base and crystalline/amorphous/solvate coverage (Claims 3 and 11–14)
- Claim 3: dosage form comprises paroxetine free base
- Claim 11: anhydrate, hydrate, or solvate forms
- Claim 12: crystalline or amorphous form
- Claim 13: crystalline form
- Claim 14: amorphous form
Breadth assessment
- These dependents cover essentially all major solid-state categories commonly used for oral pharmaceuticals: free base, salts, solvates, hydrates, crystalline, amorphous.
- From an infringement standpoint, these dependents make it harder for a competitor to “design around” using alternate solid-state forms, assuming the regimen still matches Claim 1’s dose and indication.
What does “7.5 mg/day based on the paroxetine moiety” mean for generic dosing infringement?
The dosing limitation is expressed as 7.5 mg/day based on the paroxetine moiety. That wording is typically construed to focus on equivalent paroxetine content rather than salt molecular weight.
Implications
- If a product delivers paroxetine moiety equivalent to 7.5 mg/day, it is within the dose limitation.
- A generic could still attempt design-around by using a different daily paroxetine-moiety equivalent or structuring administration outside the claimed regimen. But changing the dose is more likely to require a label change or different clinical use pattern.
Litigation friction point
- If paroxetine is administered as different salts, the moiety basis helps plaintiffs argue the dose equivalence. The defensive path is usually dose deviation, not salt switching.
What therapeutic scope does US 9,393,237 cover: hot flashes vs broader menopausal symptoms?
Claim 2 limits the thermoregulatory dysfunction condition to:
- hot flashes
- hot flushes
- night sweats
- combinations
This is narrower than “menopausal symptoms” broadly. It is also narrower than psychiatric indications where paroxetine is widely used.
Potential non-infringement framing
- If a competitor’s product is prescribed for other menopausal conditions not framed as thermoregulatory dysfunction (e.g., mood symptoms without hot flash/night sweat targeting), infringement depends on how the method claim is invoked in practice and documentation.
- In enforcement, the label, promotional materials, and prescribing behavior usually supply the “thermoregulatory dysfunction associated with menopause” tie.
How many distinct formulation variants are covered by the dependent claims?
Using the claim language provided:
Salt categories explicitly listed
- Hydrohalides
- Sulfates
- Phosphates
- Oxalate
- Tosylate
- Pamoate
- Citrate
- Carbonate
- Bicarbonate
- Maleate
- Malate
- Fumarate
Specific salts called out
- Hydrochloride (Claim 7)
- Hydrobromide and hydroiodide (Claim 6)
- Sulfate and bisulfate (Claim 8)
- Mesylate (Claim 9)
- Mono/di/tri basic phosphates (Claim 10)
- Combinations of two or more within the enumerated categories (Claims 5, 6, 8, 10)
Solid-state categories
- Free base (Claim 3)
- Anhydrate, hydrate, solvate (Claim 11)
- Crystalline (Claim 13)
- Amorphous (Claim 14)
- Crystalline or amorphous broadly (Claim 12)
Net effect: The dependent claim set is designed to eliminate the most common generic design-around levers tied to salt selection and solid-state form.
Is US 9,393,237 a formulation patent or a method-of-use patent?
It is a method for treating claim. The claims specify:
- patient group (female; menopausal thermoregulatory dysfunction),
- symptom set (hot flashes/flushes/night sweats),
- dosing regimen (paroxetine at 7.5 mg/day on paroxetine-moiety basis),
- administered dosage form parameters (free base/salt/solid-state variants).
It does not claim:
- a specific manufacturing method,
- a unique device,
- a particular controlled-release matrix,
- or an apparatus.
So infringement analysis centers on use and dose/regimen, with “dosage form comprises…” language serving to tighten the method claim to certain paroxetine forms.
What is the likely infringement theory for generics or biosimilars (US context)?
Biosimilars: Not applicable. The patent is for a small-molecule active ingredient (paroxetine).
Generics: Likely theories involve “use” infringement tied to:
- labelled dosing matching 7.5 mg/day,
- prescribing patterns directed to hot flashes/night sweats in menopausal women,
- and the paroxetine-moiety equivalent dose actually administered.
Because dependent claims cover numerous salts and solid-state forms, a generic changing from one salt to another is less likely to escape if dosing and indication match.
How does the claim architecture affect claim strength and invalidity strategies?
From a litigation strategy perspective, this patent’s scope creates a mixed profile:
Strengths for enforcement
- The independent claim is anchored on a specific clinical regimen: 7.5 mg/day paroxetine for menopausal thermoregulatory dysfunction.
- Dependent claims cover extensive formulation variants, reducing easy design-around arguments based on salt/solid state.
Typical invalidity angles for dose-and-use claims
- Prior art that already disclosed:
- paroxetine for menopausal hot flashes/night sweats,
- and specifically a 7.5 mg/day regimen (or an equivalent),
- Or prior disclosures that render the dose selection not novel or not nonobvious.
The most common focus in invalidity is therefore dose-specific prior art and predictability of dose effects for this indication.
(Those are claim-based litigation themes; the provided claim text alone does not identify the specific patent specification, filing history, or cited references.)
What does “dosage form comprises paroxetine free base” add to coverage?
Claim 3 confirms that infringement includes scenarios where the dosage form is:
- paroxetine free base, even without emphasizing salt selection.
Because Claims 4–10 already cover numerous salts, Claim 3 mainly prevents a defendant from arguing that only salt forms are intended.
How do Claims 11–14 expand the solid-state design space covered?
- Claim 11: anhydrate/hydrate/solvate
- Claim 12: crystalline or amorphous
- Claim 13: crystalline specifically
- Claim 14: amorphous specifically
These dependents make the patent resilient against solid-state substitutions. For a generic, the most meaningful design-around remains changing the dose regimen or the method use rather than altering crystal form.
What is the business risk profile of US 9,393,237 for 7.5 mg paroxetine hot flashes?
High-risk scenario
- A competitor sells a paroxetine product used to treat menopausal hot flashes/night sweats at 7.5 mg/day paroxetine-moiety equivalent.
- The product uses a paroxetine form that fits within the broad dependent claim space (salt/free base; crystalline/amorphous/solvate/hydrate).
Lower-risk scenario
- A competitor’s regimen deviates from 7.5 mg/day on a paroxetine-moiety basis.
- Or the clinical use/prescription does not fall within thermoregulatory dysfunction associated with menopause, limited to hot flashes/hot flushes/night sweats as claimed.
Key Takeaways
- US 9,393,237 is a method-of-use patent covering treatment of menopausal thermoregulatory dysfunction in female patients with paroxetine at 7.5 mg/day (paroxetine-moiety basis).
- The independent claim is narrow on population, indication, and dose. Those are the primary levers for infringement and design-around.
- Dependent claims broaden protection across paroxetine free base and many salt forms (hydrochloride, mesylate, sulfate/bisulfate, phosphates, and other enumerated acids) plus solid-state variants (hydrates/solvates, crystalline and amorphous).
- Because salt/solid-state coverage is broad, generic “form switching” is unlikely to avoid infringement if the dosing regimen and method use match Claim 1.
FAQs
1) What paroxetine dosing is required to fall within US 9,393,237?
7.5 mg/day based on the paroxetine moiety, per Claim 1.
2) Does the patent require paroxetine to be a specific salt like hydrochloride?
No. Claim 3 covers free base and dependent claims cover multiple salts, including hydrochloride, sulfate/bisulfate, mesylate, phosphates, and other enumerated pharmaceutically acceptable salts.
3) Are crystalline vs amorphous forms treated as different coverage categories?
Yes, but both are covered: crystalline (Claim 13), amorphous (Claim 14), and both broadly (Claim 12). Hydrates/solvates are also covered (Claim 11).
4) Does the patent cover all menopausal symptoms?
No. It is limited to thermoregulatory dysfunction associated with menopause, specifically hot flashes/hot flushes/night sweats and combinations (Claim 2).
5) Can a generic avoid infringement by changing only the paroxetine solid-state form?
The dependent claims are broad on solid state (anhydrate/hydrate/solvate; crystalline/amorphous), so a solid-state change alone is unlikely to remove coverage if the regimen matches Claim 1.
References
- United States Patent 9,393,237.
